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Background: Anemia often complicates chronic kidney disease (CKD), leading to insufficient
tissue oxygenation and hypoxic injury, the factor thought to underlie progression from CKD
to renal failure. Perfluorocarbons are potent oxygen transporters used in organ preservation
and synthetic blood development. Data are scarce on their relationship with kidney function,
especially in diabetes where anemia and hypoxia are more prevalent. We investigated the
relationship of perfluoroalkyl acids (PFAS) with kidney function and variation by diabetes
and anemia status.
Methods: Data on 53,650 adults (5,210 with diabetes) were obtained from the C8 Health
Project. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73
m2. Four PFAS were investigated: perfluorohexane sulfonate (PFHxS), perfluorooctanoic acid,
perfluorooctane sulfonate, and perfluorononanoic acid.
Findings: Each PFAS was positively associated with eGFR among those with CKD or anemia;
this was the strongest among those with both CKD and anemia, followed by those with CKD
uncomplicated by anemia. These relationships were more pronounced among those with diabetes
(all P<0.01). In the absence of both CKD and anemia, PFAS was inversely associated with eGFR.
Among persons with both anemia and diabetes, when further stratified by CKD stage, compared
to an eGFR <30, ORs (95% CI) for being in the eGFR ≥ 90, 60–89, 45–59, and 30–45 range,
respectively, were 3.20 (2.00–5.13), 2.64 (1.83–3.80), 3.18 (2.17–4.67), and 1.99 (1.38–2.86)
for each ng/dL increase in PFHxS. Results were similar for each PFAS.
Interpretation: PFAS are inversely associated with kidney function in CKD and diabetes,
with a stronger relation observed when anemia is present.
Keywords: diabetes, anemia, chronic kidney disease, hypoxia, perfluoroalkyl substances
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Anemia in persons with chronic kidney disease (CKD) is common.1,2 Although impaired
kidney function is thought to be the primary cause of anemia in CKD,3 particularly
among those without diabetes, low hemoglobin which is characteristic of anemia
results in reduced renal tissue oxygen delivery and thus renal ischemia.1 Renal hypoxia,
when chronic, may lead to interstitial fibrosis and sclerosis. Hypoxic injury in CKD
is thought to be the common underlying mechanism of progression to renal failure
regardless of the etiology of the kidney disease.4,5
Perfluoroalkyl acids (PFAS), a class of perfluorocarbons, are synthetic environmental contaminants with detectable levels observed in over 90% of the US population.
Possessing both hydrophobic and oleophobic characteristics, they are industrial com-
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function and whether any such association varied by diabetes,
anemia, or CKD status.

pounds used in the manufacture of a wide range of industrial
and consumer products, with waterproofing, nonstick, lubricating, or fire suppression utility, such as in Teflon cooking
products and waterproof surfactants.6 Because their strong
carbon-fluorine bonds resist environmental degradation,
PFAS are persistent environmental contaminants found in the
serum of the majority of the human populations studied.6,7
These environmental pollutants have been linked to adverse
health outcomes,6,8–10 including birth defects and certain
cancers.11–13 Their long biological half-lives of approximately
3.0–8 years and their poor ability to metabolize likely add to
any chronic health effects they may pose.8,14–18
Perfluorocarbons are oxygen carriers and, as such, they
have been tested for use in developing synthetic blood.19–21
Perfluorocarbons have also been used in the preservation
of harvested pancreases and kidneys for transplants. 22
The high oxygen transport capacity of perfluorocarbons
has been shown to reduce the hypoxia-induced damage
associated with organ preservation, such as for the kidney and pancreas.22–26 In experimental models, retrograde
renal perfusion with perfluorocarbon emulsion has also
been shown to increase systemic venous oxygenation and
renal preservation.27 There was higher systemic venous
oxygenation, a lower decrease in creatinine clearance, and
less histological evidence of ischemic damage.27 However,
earlier data in experimental studies suggested that perfluorocarbon emulsion was associated with greater renal
function impairment.28
Although PFAS have also been recently shown to have
cytotoxic potential and to induce inflammation, processes
that could adversely affect kidney function,29 the association
of PFAS with chronic disease may vary in diseases characterized by chronic hypoxia, such as diabetes and kidney
disease.4,30 This is particularly important given the relatively
high prevalence of anemia among persons with both diabetes
and CKD. For a given level of kidney function, there is a
greater prevalence of anemia among persons with diabetes relative to those without diabetes. Furthermore, while
anemia is rarely observed before stage 3 CKD is reached
among persons without diabetes, anemia is still common at
higher levels of kidney function in the diabetic population.
Data in humans on the effect of PFAS on kidney function
and CKD are scarce, especially in diabetes where kidney
hypoxia is more prevalent.31,32 Renal hypoxia occurs prior
to other manifestations of kidney disease.33 Attenuating this
hypoxia may slow the development of kidney disease. Given
the hypothesized role of chronic hypoxia on progression of
CKD,4 we investigated the relationship of PFAS with kidney

The C8 Health Project is a community-based study that investigates the health effects of exposure to perfluorooctanoic acid
(PFOA/C8).34 The C8 Health Project was created as part of a
settlement after it was found that PFOA had contaminated the
drinking water of six water districts in the mid-Ohio Valley
in West Virginia and Ohio between 1950 and 2004. A post
hoc agreement between the settling parties of the class action
lawsuit created the C8 Health Project, a community-based
health survey designed to investigate the effects of exposure
to PFOA-contaminated drinking water.34 From August 2005
to August 2006, baseline data were gathered on 69,030 individuals working or living in six PFOA-contaminated water
districts in West Virginia and Ohio, including those exposed
to contaminated private-well drinking water. The estimated
participation rate in the C8 Health Project among adult residents of the affected water districts was 81%.35 Data from
the C8 Health Project (n=69,030) were obtained for use in
the current study.
The enrollment and data collection methods for the C8
Health Project have been described in detail previously.34 The
health survey collected a wide range of serum and anthropometric measures, as well as self-reported clinician diagnoses of medical conditions. Brookmar Inc. (Parkersburg,
WV, USA) administered the consent process and conducted
the data collection. We obtained institutional review board
approval at West Virginia University for access to the C8
Health Project de-identified data for this study.
Diabetes was based on self-report of a physician diagnosis of diabetes. There were 14,573 children and adolescents
under the age of 20 years and they were excluded from the
analysis. Of the remaining 54,102 study participants, 5,296
reported a physician diagnosis of diabetes. Of the 5,296 with
diabetes and 49,161 without diabetes, 26 and 329, respectively, had missing data on the four major perfluorocarbons
of interest, and another 60 persons with diabetes and 392
without diabetes had missing data on variables needed to
calculate estimated glomerular filtration rate (eGFR), ie,
race, sex, or serum creatinine. Our final study population
thus comprised 53,650 adults, including 5,210 individuals
with and 48,440 without diabetes.
Perfluorocarbons (PFAS) were assayed using the protein
precipitation extraction method with reverse phase high-performance liquid chromatography/tandem mass spectrometry.
A triple quadrupole mass spectrometer in pre-selected reac-
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tion monitoring mode, monitoring for the M/Z transitions of
PFAS species with an internal 13C PFAS standard corresponding to the target compound, was utilized for detection of each
PFAS. Twelve PFAS were tested; however, only four were
detectable in the serum of over 90% of project participants:
perfluorohexane sulfonate (PFHxS), PFOA, perfluorooctane
sulfonate (PFOS), and perfluorononanoic acid (PFNA). Thus,
these four compounds were the focus of the current study.
Anemia was defined as a hemoglobin of <13.0 g/dL in
men and <12 g/dL in women. Hemoglobin was measured in
EDTA anticoagulated whole blood. Creatinine was measured
using a kinetic rate Jaffe method.36 eGFR was calculated
based on the CKD-EPI formula.37 CKD was defined as an
eGFR of <60 mL/min/1.73 m2.
General linear models were used to test for differences in
continuous variables, and the chi square test was used to test
for differences in categorical data. Logistic regression was
used to estimate the relationship of each of the PFAS with
CKD. Linear regression analysis using general linear models
was also used to estimate the relationship between each of
the PFAS with eGFR, stratified by anemia and CKD status.
Separate models were constructed to test for a linear trend in
the beta coefficients in the PFAS–eGFR relationship in the

four anemia-CKD groups (CKD and anemia, CKD without
anemia, anemia without CKD, neither CKD nor anemia)
for each PFAS. Multinomial logistic regression was used to
assess the relationship of PFAS with multiple stages of kidney
function impairment, with eGFR (mL/min/1.73 m2) stratified
into the following categories: ≥90 (normal), 60–89 (mild
kidney impairment), 45–59 (stage 3a CKD), 30–44 (stage
3b CKD), and <30 (stages 4–5 CKD). Multivariable models
included age, sex, and diabetes duration (in diabetes-specific
analyses), body mass index (BMI), lipids, white blood cell
count, C-reactive protein (CRP), hemoglobin, and iron. We
tested for effect modification by diabetes and CKD status on
the effect of PFOA and PFOS with eGFR. The criterion for
statistical significance was a two-tailed P-value of <0.10 for
effect modification and <0.05 otherwise. Statistical analysis
was conducted using SAS version 9.4 (Cary, NC, USA).

Results
Characteristics of the study participants by diabetes status
are presented in Table 1. Persons with diabetes tended to be
older and have a higher BMI and a lower eGFR, and were
three times more likely to have CKD. They were also three
times more likely to have anemia, an increased prevalence

Table 1 Characteristics of adult (age ≥20 years) C8 health population by diabetes status, mean ± SD, median (IQR) or % (n)
Characteristics

Diabetes
(n=5,210)

No diabetes
(n=48,440)

P-value

Age, years
Sex, male
Race, White
Diabetes duration, years
BMI, m/kg2
eGFR, mL/min/1.73 m2
Serum creatinine, mg/dL
CKD
Anemia
In those with CKD
In those without CKD
Hemoglobin, g/dL
Serum iron, µ/dL
HDLc, mg/dL
LDLc, mg/dL

57.8±13.5
49.5 (2,577)
96.3 (5,017)
5.6 (2.3–11.8)
33.1±7.5
77.4±22.5
1.02±0.42
22.5 (1,173)
12.1 (631)
28.0 (328)
7.5 (303)

45.1±15.4
47.2 (22,862)
97.4 (47,166)
–
28.3±6.1
88.1±19.1
0.94±0.26
7.1 (3,431)
3.7 (1,786)
11.6 (399)
3.1 (1,387)

14.1±1.5
78.5±29.9
45.6±12.2
98.6±36.5
7.6±3.1
2.8 (1.2–6.3)

14.6±1.4
87.5±34.7
50.1±14.6
114.1±34.7
7.3±2.2
1.8 (0.80–4.20)

<0.0001
0.002
<0.0001
–
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

2.7 (1.7–4.3)
28.6 (12.6–72.7)
21.2 (13.7–31.4)
1.4 (1.0–1.8)

3.0 (1.9–4.8)
28.0 (13.6–71.4)
20.2 (13.6–29.1)
1.4 (1.1–1.8)

<0.0001
0.15
0.11
<0.0001

White blood cell count, ×103/µL
CRP, mg/L
PFAS
PFHxS, ng/mL
PFOA, ng/mL
PFOS, ng/mL
PFNA, ng/mL

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDLc, high-density lipoprotein
cholesterol; LDLc, low-density lipoprotein cholesterol; PFAS, perfluoroalkyl acids; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic
acid; PFOS, perfluorooctane sulfonate.
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that existed even among those with CKD. Consistent with
this, they also tended to have a lower serum iron concentration than persons without diabetes. Lipid and inflammatory
marker profiles also tended to be worse in persons with
diabetes. Although there were no differences observed for
mean levels of PFOA or PFOS by diabetes, differences were
observed for PFHxS and PFNA.
The prevalence of CKD was 22% among those with
diabetes and 7% among those without diabetes. In multivariable analyses controlling for age, sex, diabetes duration (in
those with diabetes), BMI, lipids, white blood cell count,
CRP, hemoglobin, and iron, PFAS were inversely associated
with CKD in those with diabetes but positively associated
with CKD in those without diabetes (P-interaction <0.0001
for each PFAS and diabetes). This is depicted graphically
for PFOA and PFOS in Figure 1, which shows that for
every natural log increase in serum PFOA levels, those with
diabetes had an 8% reduction in the likelihood of having
CKD whereas those without diabetes had a nonsignificant
1% reduced likelihood. For PFOS, there was a 20% reduced
likelihood of CKD for those with diabetes with each natural
log increase in serum PFOS levels, but an 8% increase in the
odds of CKD for those without diabetes. Similar relationships
were also observed for PFHxS and PFNA exposure.

Dovepress

Figure 2 shows the multivariable adjusted relationship of
each of the PFAS with kidney function, stratified by anemia
and CKD status among those with (Figure 2A) and without
(Figure 2B) diabetes. In the absence of diabetes, for each
of the PFAS, the strongest relationship was among those
with both anemia and CKD, which demonstrated a positive
relationship, ie, an increased eGFR. This was followed by a
moderate, though still positive, relationship among those with
CKD but no anemia. In the diabetic population with anemia
but no CKD, a weak, though still positive, relationship was
observed between the PFAS and eGFR. For those with neither
anemia nor CKD, PFAS demonstrated an inverse relationship
with eGFR. The P-value for linear trend for the beta coefficients in the strength of the relationship of perfluoroalkyl
substances with eGFR among the four anemia-CKD groups
was <0.0001 for each PFAS.
Figure 2 also shows that the same general pattern in the
relationship of PFAS with kidney function by anemia and
CKD status that was observed for those with diabetes was
apparent in those without diabetes as well. The strongest
relationship was observed among those with both anemia
and CKD, with the relationship progressively becoming
attenuated before becoming inversely related among those
with neither anemia nor CKD. However, except for those with

Figure 1 Relationship of PFOA and PFOS with CKD, stratified by diabetes status. Gray lines = PFOA. Black lines = PFOS. Analyses adjusted for age, sex, BMI, HDLc, LDLc,
white blood cell count, CRP, hemoglobin, and iron.
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CRP, C-reactive protein; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein
cholesterol; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.
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Figure 2 (A) Relationship of perfluoroalkyl substances with eGFR among the C8 Health Population, among persons with diabetes, stratified by anemia and CKD status.
P-value <0.0001 for linear trend for the beta coefficients in the strength of the relationship of each of the perfluoroalkyl substances with eGFR among the four anemia-CKD
groups. (B) Relationship of perfluoroalkyl substances with eGFR among the C8 Health Population, among persons without diabetes, stratified by anemia and CKD status.
P-value<0.0001 for linear trend for the beta coefficients in the strength of the relationship of each of the perfluoroalkyl substances with eGFR among the four anemia-CKD
groups.
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PFAS, perfluoroalkyl acids; PFHxS, perfluorohexane sulfonate; PFNA,
perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.

neither anemia nor CKD, the relationships between PFAS and
eGFR tended to be weaker among those without diabetes.
In the population as a whole, for each natural log increase
in PFAS there was an approximately two- to fourfold greater
odds of being in the normal eGFR range than in the stage
4–5 CKD range. Odds ratios (95% CIs) for being in one of
the three other eGFR categories >30 mL/min/1.73 m2, ie,
CKD stages higher than 4, were 2.25 (1.89–2.67) to 2.50

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2018:11

(2.14–2.92) for PFHxS, 1.61 (1.44–1.81) to 1.66 (1.48–1.86)
for PFOA, 1.88 (1.68–2.11) to 2.38 (2.11–2.68) for PFOS,
and 2.84 (2.29–3.54) to 3.68 (2.89–4.69), for PFNA, data
not depicted. Thus, results were similar, but generally attenuated for stages 2, 3a, and 3b, ie, a two- to fourfold greater
likelihood of being in a higher eGFR range than in the <30
range. This was true regardless of diabetes status, although
the relationship was generally stronger among persons with

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

711

Dovepress

Conway et al

Table 2 Multivariable adjusteda association of PFAS with stage of kidney function, stratified by diabetes status, OR (95% CI)
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PFHxS
<30, mL/min/1.73 m2
30–44, mL/min/1.73 m2
45–59, mL/min/1.73 m2
60–89, mL/min/1.73 m2
≥90, mL/min/1.73 m2
PFOA
<30, mL/min/1.73 m2
30–44, mL/min/1.73 m2
45–59, mL/min/1.73 m2
60–89, mL/min/1.73 m2
≥90, mL/min/1.73 m2
PFOS
<30, mL/min/1.73 m2
30–44, mL/min/1.73 m2
45–59, mL/min/1.73 m2
60–89, mL/min/1.73 m2
≥90, mL/min/1.73 m2
PFNA
<30, mL/min/1.73 m2
30–44, mL/min/1.73 m2
45–59, mL/min/1.73 m2
60–89, mL/min/1.73 m2
≥90, mL/min/1.73 m2

Diabetic population

Non-diabetic population

Ref
2.05 (1.57–2.68)
2.68 (2.07–3.47)
2.77 (2.16–3.56)
2.49 (1.92–3.23)

Ref
2.30 (1.83–2.90)
2.37 (1.87–2.84)
2.29 (1.86–2.81)
2.07 (1.69–2.55)

Ref
1.48 (1.23–1.80)
1.47 (1.23–1.76)
1.56 (1.31–1.89)
1.57 (1.31–1.90)

Ref
1.69 (1.44–2.00)
1.70 (1.46–1.98)
1.71 (1.47–1.99)
1.66 (1.42–1.93)

Ref
1.90 (1.54–2.35)
2.34 (1.92–2.87)
2.51 (2.07–3.03)
2.32 (1.90–2.84)

Ref
2.47 (2.04–3.00)
2.36 (2.02–2.75)
2.12 (1.83–2.44)
1.78 (1.54–2.06)

Ref
3.08 (2.10–4.54)
3.27 (2.28–4.68)
3.74 (2.63–5.31)
3.90 (2.70–5.65)

Ref
4.04 (2.94–5.54)
3.58 (2.71–4.73)
3.16 (2.41–4.15)
2.64 (2.10–3.48)

Notes: aAnalyses adjusted for age, sex, BMI, HDLc, LDLc, white blood cell count, CRP, hemoglobin, and iron.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol; PFAS, perfluoroalkyl
acids; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.

diabetes (Table 2). There was a trend toward a stronger effect
of PFAS in the highest eGFR group with diabetes and anemia. The odds were generally lowest in those with anemia
uncomplicated by diabetes, although they were still twice
as likely to be in this category compared to the eGFR <30
category with each natural log increase in PFAS (Table 3).

The major finding of this study is that PFAS demonstrated
a linear trend in the positive relationship with eGFR based
on anemia-CKD status that represented a gradient of renal
hypoxia. The strongest positive relationships were observed
for those with both anemia and CKD, followed by those
with CKD but no anemia. Little relationship was observed
between PFAS and eGFR among those with anemia in the
absence of CKD, while for those with neither anemia nor
CKD an inverse relationship was observed between PFAS
and eGFR. These associations were observed both among
those with and without diabetes, although more pronounced
among those with diabetes. We also found that persons with
higher PFAS levels were two to four times more likely to be

in the normal to mild kidney impairment range, or stages 3a
or 3b CKD, than in stages 4–5 CKD. Our data suggest that
the high oxygen carrying capacity of PFAS may be beneficial
for renal function among persons with CKD, likely due to
protection against hypoxia-induced progression toward renal
failure. Our data also suggest that this protective relationship
may be more pronounced in diabetes.
Perfluorocarbons are hydrogen carbon chains in where
the hydrogen atoms have been replaced by fluorine. This
fluorine substitution of hydrogen makes PFAS very efficient
oxygen carriers. The oxygen solubility of perfluorocarbons
has been reported to be 25 times greater than either blood
or water.22,38 However, their oxygen binding constant is negligible, and thus they are more efficient than hemoglobin in
delivering oxygen to surrounding tissues. As such, they have
been used as blood substitutes,19,20 in the development of
synthetic blood, and in the preservation of organs harvested
for transplants.22 The high oxygen transport ability of perfluorocarbons has been shown to reduce the hypoxia-induced
organ damage associated with kidney and pancreas organ
preservation.22,23,25 We speculate that it is this high oxygen
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Table 3 Multivariable adjusteda association of PFAS with stage of kidney function, stratified by diabetes and anemia status, OR (95% CI)
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Characteristics
PFHxS
<30, mL/min/1.73 m2
30–44, mL/min/1.73 m2
45–59, mL/min/1.73 m2
60–89, mL/min/1.73 m2
≥90, mL/min/1.73 m2
PFOA
<30, mL/min/1.73 m2
30–44, mL/min/1.73 m2
45–59, mL/min/1.73 m2
60–89, mL/min/1.73 m2
≥90, mL/min/1.73 m2
PFOS
<30, mL/min/1.73 m2
30–44, mL/min/1.73 m2
45–59, mL/min/1.73 m2
60–89, mL/min/1.73 m2
≥90, mL/min/1.73 m2
PFNA
<30, mL/min/1.73 m2
30–44, mL/min/1.73 m2
45–59, mL/min/1.73 m2
60–89, mL/min/1.73 m2
≥90, mL/min/1.73 m2

Diabetic population

Non-diabetic population

Anemia

No anemia

Anemia

No anemia

Ref
1.99 (1.38–2.86)
3.18 (2.17–4.67)
2.64 (1.83–3.80)
3.20 (2.00–5.13)

Ref
2.15 (1.42–3.27)
2.66 (1.79–3.95)
2.89 (1.97–4.24)
2.55 (1.73–3.77)

Ref
1.69 (1.17–2.44)
1.73 (1.23–2.44)
1.72 (1.25–2.36)
1.80 (1.29–2.52)

Ref
2.71 (2.02–3.65)
2.66 (2.02–3.49)
2.63 (2.01–3.45)
2.37 (1.81–3.11)

Ref
1.28 (0.99–1.65)
1.33 (1.04–1.70)
1.41 (1.11–1.80)
1.79 (1.33–2.42)

Ref
1.83 (1.34–2.50)
1.75 (1.30–2.35)
1.84 (1.37–2.47)
1.82 (1.36–2.46)

Ref
1.60 (1.24–2.06)
1.74 (1.37–2.21)
1.53 (1.22–1.91)
1.59 (1.26–2.02)

Ref
1.72 (1.37–2.15)
1.69 (1.37–2.10)
1.72 (1.39–2.12)
1.67 (1.35–2.06)

Ref
2.20 (1.58–3.07)
2.47 (1.78–3.43)
2.27 (1.68–3.07)
2.83 (1.88–4.26)

Ref
1.74 (1.31–2.34)
2.33 (1.77–3.06)
2.58 (1.99–3.34)
2.33 (1.78–3.05)

Ref
1.98 (1.42–2.74)
2.08 (1.54–2.80)
1.82 (1.42–2.33)
2.09 (1.58–2.77)

Ref
2.77 (2.17–3.53)
2.49 (2.05–3.02)
2.24 (1.86–2.69)
1.86 (1.54–2.24)

Ref
3.16 (1.86–5.37)
3.30 (1.98–5.47)
3.33 (2.03–5.47)
4.38 (2.28–8.42)

Ref
3.17 (1.74–5.80)
3.49 (2.00–6.11)
4.13 (2.40–7.13)
4.25 (2.44–7.43)

Ref
3.23 (1.92–5.44)
2.73 (1.70–4.38)
2.49 (1.61–3.85)
2.59 (1.62–4.16)

Ref
4.31 (2.87–6.49)
3.82 (2.66–5.50)
3.36 (2.35–4.81)
2.79 (1.95–4.00)

Notes: aAnalyses adjusted for age, sex, BMI, HDLc, LDLc, white blood cell count, CRP, hemoglobin, and iron.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol; PFAS, perfluoroalkyl
acids; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.

carrying capacity that accounted for the positive relationship between PFAS and eGFR among those with CKD in
our population, as CKD is a state where hypoxia greatly
accelerates the progression to renal failure. The stronger
relationship of the sulfonate PFAS (PFHxS and PFOS),
whose half-lives are generally much longer than PFOA,17,18
supports this. By circulating longer in the system, their
potential protection from hypoxia-induced glomerular damage would be prolonged and thus the relationship of eGFR
with those particular PFAS would be stronger.
The chronic hypoxia theory postulates that after an initial
insult or injury to the kidney, there is some scarring that
leads to hypoxia because of the greater diffusion distance to
capillaries.4,30,39,40 This capillary hypoxia results in fibroblast
deposition, the laying down of extracellular matrix and neutrophils. This leads to more sclerosis and hypoxia, a cycle
which eventually results in organ failure. Diabetes, whether
it be through increased formation of advanced glycation end
products and the structural changes they cause on kidney
tubules, or via the increased oxygen renal consumption

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2018:11

resulting from hyperglycemia, may be an insult to the kidney resulting in increased hypoxia. Hyperglycemia results
in greater renal oxygen consumption to transport sodium.31
This leads to greater renal blood flow and its sequelae of
hyperfiltration. This hyperfiltration may eventually result in
hypoxia due to the increased oxygen consumption.
Earlier data in experimental studies suggested that
perfluorocarbon emulsion was associated with greater
renal function impairment;28 however, more recent data in
experimental models found that retrograde renal perfusion
with perfluorocarbon emulsion increased systemic venous
oxygenation and renal preservation.27 There was higher
systemic venous oxygenation, a lower decrease in creatinine
clearance, and less histological evidence of ischemic damage.27 The results of the natural experiment we report on
suggest that the high oxygen carrying capacity of the PFAS
that were circulating in the blood and bathing the tissues of
the C8 Health Population were protective against hypoxiainduced decline in kidney function in those with CKD. This
relationship appeared to be stronger in those with diabetes, for
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whom chronic hyperglycemia-induced oxygen consumption
would likely normally result in increased hypoxia.
In general population data from the National Health and
Examination Survey for the years 1999–2008, the perfluoroalkyl substances PFOA and PFOS were positively associated
with the presence of CKD and inversely associated with
eGFR.41 As in our population, in the NHANES population
their relationship with eGFR was stronger in persons without
CKD. Although the authors performed subgroup analyses by
age, sex, race, educational level, and BMI, diabetes was only
used as a co-variable and controlled for in the analyses. Similarly, in a study conducted by the C8 Health Study science
panel investigating the relationship of PFOA with chronic
diseases in the current study population, analyses examining
the relationship between PFOA and kidney disease in the
population as a whole as well as specifically in those without
diabetes were conducted. However, the relationship of PFOA
in those with diabetes was not examined, nor whether there
was an interaction by diabetes status.
Consistent with what is known about anemia in diabe42–44
we observed high frequencies of anemia among the
tes,
diabetic population with CKD relative to the non-diabetic
population with CKD. There was also a much greater prevalence of anemia among persons with diabetes in the non-CKD
population. Anemia is a condition in which red blood cell
mass decreases below the level needed to meet physiological
needs. As a primary function of red blood cells is to deliver
oxygen from the lungs to tissues, anemia is thus essentially a
decreased ability of the blood to oxygenate tissues, resulting
in tissue hypoxia. Reduced red cell mass leads to reduced
renal tissue oxygenation. In the context of CKD, where renal
damage has already been established, this hypoxia leads
to further nephron destruction and renal interstitial injury
and fibrosis. Since the peritubular interstitial cells are the
primary producers of erythropoietin, which in turn generates hemoglobin, the consequent reduction in functional
renal mass due to the hypoxia-induced nephron destruction
and renal interstitial fibrosis results in a feed forward cycle
toward renal failure.
We found a strong positive relationship between PFAS
and eGFR in our CKD population with anemia. This was true
regardless of the presence of diabetes, although the relationship appeared to be stronger among those with diabetes. To
a lesser extent, though still strong, this apparently protective relationship was also observed in the CKD population
without anemia. Very weak relationships were observed
between PFAS and eGFR in the anemic population in the
absence of CKD. Thus, the apparent salutary relationship

of PFAS among persons with kidney disease appears to be
its enhanced tissue oxygenation, and thus protection from
hypoxia. This relationship is particularly strong in the subpopulation with very low hemoglobin levels, ie, the population with anemia. The profound relationship we saw between
PFAS and eGFR among persons with CKD complicated by
anemia is analogous to the effect of perfluorocarbon use in
acute normovolemic hemodilution during surgery, where
perfluorocarbon-carried oxygen is preferentially, as compared
to hemoglobin, delivered to tissues.19
Despite its ubiquitous presence and its relationship with
accelerated progression to renal failure and reduced quality of life, treatment of anemia in CKD is controversial.
Treatment of anemia with erythropoietin-stimulating agents
(ESAs), although associated with an increased quality of life,
has not been shown to prolong survival.45,46 To the contrary,
ESAs have been associated with increased cardiovascular
complications of kidney disease and mortality.45,47 Our data
suggest that among persons with CKD, development of perfluorocarbon therapeutics for the treatment of renal hypoxia
may be a safer alternative.
Our study has several limitations. First, due to the
cross-sectional nature of our data, we cannot say that PFAS
are protective against progression of CKD. Our measurement was a single snapshot in time. PFAS are known to be
preferentially excreted by the action of organic anion transporter proteins (OATs). PFAS are filtered at the glomerulus,
secreted into the urine by OAT1 transporters on the tubule,
and reabsorbed from the urine by OAT4 transporters in the
tubule. Thus, if there are changes to some but not all of these
components, the serum levels could change but it may not
reflect the levels when the injury was occurring. However, if
the chronic hypoxia hypothesis of the progression of CKD
is true, then given the high oxygen carrying and diffusion
capacity of PFAS, this entire transport process of PFAS from
the glomerulus, the excretion of PFAS into the urine by OAT1
transporters on the tubule, and then the reabsorption from
the urine to the tubules by OAT4 transporters would support
a protective role of PFAS in the progression of CKD.
It could also be argued that the inverse relationship
between PFAS and CKD in our population was due to reverse
causality since those with CKD would have a decreased ability to filter PFAS, resulting in higher PFAS levels. However,
if reverse causality was the explanation of our findings, we
should have also observed an inverse relationship between
eGFR and PFAS, ie, increasing PFAS with decreasing eGFR,
in those with CKD. In fact, the opposite was observed.
However, we did observe an inverse relationship between
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PFAS and eGFR in those without CKD. We posit that this
inverse relationship in those without CKD was due to reverse
causality, as also suggested in the study by Dhingra et al,48
since the initial insult resulting in the progressive hypoxicscarring cycle had not occurred yet in those without CKD,
and thus this salutary effect of the high oxygen carrying and
diffusion capacity of the perfluorocarbons on renal tubules
would not be operant in those with normal or mildly impaired
renal function. The fact that there was an apparent threshold
effect, ie, PFAS were fairly similarly associated with being
in any one of the higher kidney function strata than in the
eGFR <30 strata, supports the hypothesis of hypoxia-induced
progression from CKD to renal failure. Our data suggest that
PFAS may protect against this. Further evaluation in animal
models would be useful.
In conclusion, although the cross-sectional nature of our
study limits causal inferencing, the strong, positive associations observed between PFAS and kidney function in those
with CKD, and to a lesser extent anemia, suggest that PFAS
may protect against further decline in renal function in these
populations. Owing to the increased hypoxia in diabetes,
these substances may have an even stronger salutary effect
on renal function in persons with diabetes complicated by
kidney disease. Given the strong evidence linking hypoxia
to progression of CKD, the high oxygen carrying capacity
of PFAS, and the suggestive findings of our study, prospective studies examining the relationship of PFAS with renal
function decline in persons with CKD, anemia, and diabetes
are warranted.
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